Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C

Mary Naguib¹, Wael Abdel-Razek², Suzanne Estaphan²,³,⁴*, Eman Abdelsameea², Mohamed Abdel-Samiee², Nevine F. Shafik⁵

¹ Clinical and Chemical Pathology, National Liver Institute, Menofia University, Shebeen El-Kom, Egypt, ² Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Shebeen El-Kom, Menoufia, Egypt, ³ Physiology Department, Faculty of Medicine, Cairo University, Giza, Egypt, ⁴ ANU Medical School, Australian National University, Canberra, Australian Capital Territory, Australia, ⁵ Clinical and Chemical Pathology Department, National Cancer Institute, Cairo University, Giza, Egypt

* suzanne.estaphan@anu.edu.au, sestaphan@kasralainy.edu.eg

Abstract

Background
The role of thrombotic factors in the pathogenesis and progression of liver fibrosis remains obscure. We aimed to study the relationship between prothrombin G20210A (PT20210) and factor V Leiden (FVL) mutations and the progression of fibrosis and liver function in chronic HCV patients.

Methods
The study included 100 subjects, 88 patients with HCV-related cirrhosis (compensated: 38, decompensated: 50), and 12 controls. Patients with other viral hepatitis or coinfection, inherited metabolic disease, autoimmune hepatitis, hepatic or extrahepatic malignancy, in addition to patients with causes of hypoalbuminemia, elevated bilirubin or prolonged INR not related to cirrhosis were excluded from the study. Relevant clinical data were collected and basic laboratory tests were performed. Liver fibrosis was assessed using APRI and FIB-4 scores. FVL and PT20210 mutations were analyzed.

Results
FVL and PT20210 mutations were significantly higher in decompensated vs. compensated patients (32% vs. 5.3%, P = 0.001; 20% vs. 5.3%, 0.043, respectively) and absent in controls. Both mutations significantly correlated to the duration of infection, platelet count and fibrosis scores. PT20210 mutation significantly correlated to serum albumin and INR. Both mutations significantly predicted fibrosis scores, especially PT20210 (AUROC: 0.833 for APRI and 0.895 for FIB-4).
Conclusions
Both mutations are significantly correlated to fibrosis progression and liver profile and could be considered as markers predicting the need for early and different intervention.

1 Introduction
Hepatitis C virus (HCV) infection is a major worldwide health problem. The highest prevalence of HCV in 2015 was detected in the Eastern Mediterranean region [1, 2]. In Egypt, the Health Issues Survey (HIS) showed a prevalence of HCV seropositivity of 10% in 2015 [3]. However, screening of about 50 million adult citizens, which started in October 2019, revealed that 4.61% had positive HCV antibodies [4].

Chronic hepatitis C occurs in a range of 70 to 80% of cases who contract HCV, which causes damage and progression to cirrhosis within 2–3 decades in 20% of patients; 25% of these patients will develop complications, such as portal hypertension, liver decompensation and hepatocellular carcinoma (HCC), with an average 5-year survival rate of 50% [5].

On the other hand, many HCV-infected patients do not develop liver-related complications even after many years of infection [6]. Therefore, it is essential to study diverse factors that might affect disease progression to early approach the patients with expected complications.

Hypercoagulability is assumed to be a contributing factor for development of liver fibrosis and its progression in chronic liver disease [7]. Thrombin as the end product of coagulation cascade [8] was thought to play a critical role in activating hepatic stellate cells (HSCs) either through binding to protease activated receptor 1 (PAR1) [9] or through induction of activation of TGF-β [10] which is a potent activator of HSCs [11].

Another possible theory depicts formation of occlusive thrombi through thrombin production which results in ischemia, parenchymal destruction ending in liver fibrosis and cirrhosis [12].

FV Leiden (G1691A) and prothrombin (G20210A) mutations are well-known genetic primary hypercoagulable risk factors [13]. Single nucleotide polymorphism of FV Leiden (G1691A) results in amino acid substitution of arginine for glutamine at position 506 of the protein (R506Q), which is one of the cleavage sites of activated protein C (APC). The mutated protein is more resistant to APC cleavage impairing the negative feedback on the coagulation cascade [14].

In addition, it hinders its role in inactivation of FVIIIa [15]. On the other hand, G→A transition in nucleotide 20210 in the 3'-untranslated region leads to an impaired 3'-end cleavage signal, resulting in RNA accumulation and thus, increased prothrombin synthesis [16]. Thus, carriers of these mutations are at high risk of developing venous thromboembolisms [17].

Previous studies have reported the role of thrombotic factors in the development and progression of liver fibrogenesis [18, 19]. However, this role is not clear enough especially with mutations of the thrombotic factors.

Our study aimed to examine the association between prothrombin and factor V Leiden mutations and the progression of fibrosis and liver function in patients infected with HCV.

2 Materials and methods
2.1. Experimental subjects
This case-control study included 100 subjects between October 2018 and April 2019. A total of 88 adult patients with HCV-related liver cirrhosis were enrolled from the Hepatology and
Gastroenterology Department, National Liver Institute, Menoufia University. Cirrhosis was confirmed by clinical examination and radiological findings. Cirrhosis is classified in 2 prognostic stages, compensated and decompensated cirrhosis, based on presence or absence of clinically evident decompensating events especially variceal hemorrhage, ascites and hepatic encephalopathy [HE] [20]. Child-Pugh class A patients were categorized as compensated and Child-Pugh class B or C as decompensated cirrhosis [21]. Duration of infection was assessed in years from the presumed date of infection. Nearly all the patients received tartar emetic injection which was the mass anti-schistosomal treatment in Egypt between 1950s and 80s. The date of tartar emetic injection was presumed as the date of HCV infection [4]. Patients were assessed for antiviral therapy and sample withdrawal was done before starting treatment. Patients with other viral hepatitis coinfection, as hepatitis B virus (HBV), inherited metabolic disease, autoimmune hepatitis, or hepatic or extrahepatic malignancy were excluded from the study. Patients with causes of hypoalbuminemia (nephrotic syndrome or diabetic nephropathy), elevated bilirubin (hemolysis or biliary obstruction) or prolonged INR (use of anticoagulants) not related to cirrhosis were also excluded. Twelve apparently healthy subjects were included as controls from the blood donation unit of National Liver Institute, Menoufia University. They had normal liver tests and were seronegative for viral hepatitis B and C.

This study was approved by the local institutional review board. Written informed consents were obtained from all eligible subjects before they were enrolled into the study. The study conforms to The Code of Ethics of the World Medical Association (Declaration of Helsinki), printed in the British Medical Journal (18 July 1964).

2.2. Routine laboratory investigations
All the included subjects had a thorough history taking, clinical examination and abdominal ultrasonography. Blood samples were obtained for complete blood count [Sysmex XT-1800i (Sysmex Corporation, Kobe, Japan)], liver and renal tests, anti-HCV, HB surface Ag (HBsAg), anti HB core IgG (anti-HBc IgG) and alpha-fetoprotein [Cobas 6000 (Roche Diagnostics GmbH, Mannheim, Germany)]. Prothrombin time and international normalized ration (INR) were assessed using Sysmex CS-1600 (Sysmex Europe GmbH, Norderstedt, Germany).

2.3. Evaluation of fibrosis
Stage of fibrosis was assessed noninvasively using the FIB-4 [22] and aspartate aminotransferase (AST) to platelet ratio index (APRI) [23] scores as follows:

\[
\text{FIB-4} = \frac{\text{Age (years)} \times \text{AST (IU/l)}}{\text{Platelet count (x10^9/l) \times \sqrt{\text{ALT (IU/l)}}}}
\]

\[
\text{APRI} = \frac{\text{AST (IU/l)} / \text{AST upper limit of normal (IU/l)}}{\text{Platelet count (x10^9/l)}}
\]

2.4. Studying factor V Leiden (G1691A) and prothrombin (G20210A) mutation
The genomic DNA was isolated from the peripheral blood of all subjects using QIAamp DNA blood Mini Kit (Qiagen, Hilden, Germany) following standard procedures according to the manufacturer’s instructions. Genomic DNA was examined for quality and quantity using the NanoDrop®-1000 spectrophotometer (Nanodrop Technologies, Inc., Wilmington, NC). Analyses of gene mutations of FVL and PT20210 were performed using hydrolysis probes via snpsig real-time PCR mutation detection/ allelic discrimination kit (Applied Biosystems...
Inc., CA, USA), in a lightCycler instrument (Roche Diagnostics, Mannheim, Germany). Genotyping reaction mix included 20 ng of whole blood genomic extracted DNA and the following reagents: 1 μL of primer / probe mix (Genotyping primer/probe mix contains two labelled probes homologous to the wild and mutant genotypes under investigation.), 10 μL Taqman universal master mix II No UNG (Catalog no. 4440040), and complete volume to 25 μL using RNase/DNase free water. A negative control was included in each reaction to exclude DNA contamination. The thermal cycling profile was 2 min at 95˚C for enzyme activation followed by 10 cycles of 10 s DNA denaturation at 95˚C, 60 s extension at 60˚C, followed by 50 cycles of 10 s DNA denaturation at 95˚C, 60 s extension at 66˚C where the fluorogenic data were collected through the ROX and VIC channels.

2.5. Statistical methods
Controls and patients with compensated and decompensated cirrhosis were compared using ANOVA then post-hoc Tukey’s test for intergroup comparisons regarding quantitative variables and Chi-square test for categorical variables. Spearman’s non-parametric correlations between FVL and PT20210 mutations and other variables were assessed. The ability of FVL and PT20210 mutations to predict fibrosis as assessed by FIB-4 and APRI was tested with the receiver-operating characteristics (ROC) curve and area under the ROC curve (AUROC).

Data were analyzed using IBM SPSS Statistics for Macintosh, Version 22.0 (IBM Corp, Armonk, NY, USA). All analyses were two-sided and P less than 0.05 was considered statistically significant.

3 Results
3.1. Characteristics of hepatitis C cirrhotic patients
This study included 88 patients with HCV-related liver cirrhosis, 38 (43.2%) with compensated, 50 (56.8%) with decompensated cirrhosis, and 12 controls. Controls and patients with compensated and decompensated cirrhosis had similar gender distribution as they were mostly males (66.7%, 57.9%, 64% respectively, P = 0.792). Controls had significantly younger age than both the compensated and decompensated groups (48 ± 4.1, 56.3 ± 6.5, 59.6 ± 7.6 years, respectively). Patients with compensated and decompensated cirrhosis were comparable regarding age (Table 1).

When compared to patients with compensated cirrhosis, those with decompensated cirrhosis had significantly higher AST, alkaline phosphatase, serum total bilirubin, urea and creatinine, and INR, and more advanced fibrosis as reflected by the APRI and FIB-4 scores. They also had significantly shorter duration of infection, lower prothrombin concentration, albumin, hemoglobin, white blood cell and platelet count (Table 1).

3.2. Prevalence of factor V Leiden (G1691A) and prothrombin G20210A polymorphisms
Both mutations could not be detected in the control subjects. In the studied patients with cirrhosis, the prevalence of FVL and PT20210 mutant polymorphisms was 20.5% and 13.6% respectively. The difference between patients and controls in the distribution of FVL or PT20210 mutations failed to reach statistical significance (P = 0.576 and 1.000, respectively). No homozygous mutations were detected for FVL or PT20210 mutation.

The mutant forms of FVL and PT20210 polymorphism were significantly higher in the decompensated group compared to the compensated group (P = 0.001and 0.043, respectively, Table 1).
3.3. Associations of factor V Leiden and prothrombin G20210A polymorphisms

Both FVL and PT20210 polymorphisms had significant positive correlation with APRI score (P = 0.049 and 0.004, respectively) and FIB-4 (P = 0.027 and 0.001, respectively), and negative correlation with platelet count (P = 0.036 and 0.001, respectively) and duration of infection (P = 0.008 and 0.010 respectively). PT20210 polymorphism was significantly positively correlated with INR (P = 0.016) and significantly negatively correlated with GGT, prothrombin concentration and serum albumin (P = 0.030, 0.025 and 0.003, respectively) (Table 2).

3.4. Prediction of fibrosis in patients using factor V and factor II polymorphisms

The ROC curve was used to assess the ability of FVL and PT20210 polymorphisms to predict FIB-4 and APRI scores, non-invasive indices of fibrosis, in patients with HCV-related cirrhosis. Both polymorphisms predicted significantly FIB-4 and APRI scores. However, the
polymorphism of PT20210 had a higher AUROC when compared to that of FVL in prediction of both APRI (0.833 vs. 0.660, respectively) and FIB-4 (0.895 vs. was 0.689, respectively) (Table 3 and Fig 1).

4 Discussion

Chronic infection with HCV has been an extensive health problem in Egypt [24]. Liver fibrosis is an inevitable consequence of chronic hepatitis C, which may result in development of liver cirrhosis and portal hypertension if left untreated [25].

With the revolutionary treatment of HCV with oral direct acting antivirals (DAAs), high cure rates in different clinical settings are achieved, including elderly patients, end-stage renal disease patients and those with cirrhosis [26]. However, still several disputes remain including hard to- cure cirrhosis [27].
Thus studying different factors that affect progression of fibrosis could help to identify high risk patients for development of complication of fibrosis to be recruited in early antiviral treatment and continually followed up. Also, it might provide data for development of new therapies for those patients.

Thrombosis might play an influential role in the progression of liver fibrosis [28]. Thrombin not only leads to thrombosis, but also activates liver stellate cells and promotes fibrogenesis through activation of fibrogenic factors such as transforming growth factor TGF-β. Also, ischemia associated with local thrombosis of portal sinusoids up-regulates the expression and secretion of profibrogenic factors including platelet derived growth factor (PDGF). FVL polymorphism prevents normal anti-thrombin activity of activated protein C and can accelerate the fibrogenetic process [29].

Therefore, we aimed to study the potential effect of PT20210 and FVL mutations on progression of fibrosis and liver function.

The FVL and PT20210 mutant polymorphisms could not be detected in the control subjects. Moreover, no homozygous mutations could be detected for FVL or PT20210 mutation in the studied controls or patients. These findings are similar to previous reports studying thrombophilic tendency among Egyptian population. Both Yaman et al [30] and El Baz et al [31] couldn’t detect FVL mutation in control and Fawzy et al [32] and Essa et al [33] reported no PT20210 mutation in control. Jadaon [34] stated that Prothrombin G20210A mutation was found to be very rare or even absent in Asian and African populations. Besides, Yaman et al [30] and Fawzy et al [32] could not detect homozygous mutation of FVL in patient or control groups, however, El Baz et al [31] and Essa et al [33], described homozygosity of both FVL G1691A and PT 20210 in patient groups. These differences could be due to small sample sizes and studying different presentations of thrombophilic tendency.

There was significant positive correlation between FVL and PT20210 mutations and the non-invasive markers of fibrosis, APRI and FIB-4. Previous studies reported increased fibrosis progression with both mutations [35, 36]. Wright et al. reported the significant correlation between FVL mutation, specifically, and the rate of progression of fibrosis in chronic HCV patients [36]. However, they did not find significant association between prothrombin mutation and rate of fibrosis. Poujol-Robert et al. [37] highlighted the importance of APC
resistance as an independent risk factor for cirrhosis progression. On the other hand, Mahershak et al. found that the presence of the PT20210 mutation caused fast progression of liver fibrosis [38], however, they could not detect significant association between FVL mutation and rate of fibrosis progression, which they explained could be due to their relatively small sample size [38].

In contrast, Dik et al. [28] could not detect correlation between PT20210 or FVL mutations and fibrosis progression rate. This could be due to differences in studied population. They noticed that highest fibrosis progression rate was in Caucasian and Black patients than in Asians. Also they reported that rate of fibrosis progression was higher in chronic HCV patients than chronic HBV patients. However, they stated that factor XIII Val34Leu mutation was a risk factor for an increased rate of liver fibrogenesis in patients with chronic hepatitis B or C infection [28]. Goulding et al., [39] denied the impact of FVL or PT20210 polymorphisms on fibrosis scores in HCV-infected patients as well. This could be due to the low overall fibrosis stage in their study making it difficult to observe any difference. In addition, the mean interval time of his study was too short to definitively assess the rate of fibrosis progression.

Both mutations were significantly correlated to the platelet count which was significantly lower in patients with decompensated cirrhosis compared to the compensated group. Together with the significantly higher prevalence of both mutations in the decompensated vs. compensated groups, we could deduce that FVL and PT20210 mutations are associated with the portal pressure, for which the platelet count is an indirect marker, and which is another complication of liver fibrosis.

Interestingly, patients with decompensated cirrhosis had a significantly shorter presumed duration of infection and higher prevalence of both mutations when compared to those to compensated cirrhosis. These findings could imply that patients with decompensated cirrhosis are rapid fibrosers. This could be partly explained by the higher prevalence of the mutations of these thrombotic factors.

We further studied the effect of both mutations on the synthetic function of the liver. We noticed that PT20210 and FVL were significantly associated with liver decompensation. PT20210 mutation significantly correlated to synthetic functions of the liver, as reflected by serum albumin, prothrombin concentration and INR. Both mutations correlated to platelet count and duration of infection. Previously, Goulding et al. [39] detected significantly lower ALT levels for factor V wild type compared to heterozygotes. However, to the best of our knowledge, this is the first study to assess the correlation of coagulation factor mutations with the progression to decompensation. Clinical implication of our findings is strict follow up of patients with cirrhosis who have such mutations due to high risk of developing complications and also it will be beneficial to know their potential role in the pathogenesis of fibrosis that may be a target of therapy in the future. Screening of hepatocellular carcinoma in rapid fibrosers with such mutation may be warranted.

Limitations of our study include that it was a single center study, which included only one etiology of liver disease, HCV-related liver cirrhosis, and with no prospective follow-up.

5 Conclusions

Our study has demonstrated that factor V Leiden (G1691A) and prothrombin G20210 mutant polymorphisms are significantly correlated with the liver fibrosis, synthetic function. Notably, both mutations, especially PT20210 significantly predicted liver fibrosis. This could reflect the role of thrombotic mutations in the pathogenesis of fibrosis and could be the target of future antifibrotic therapies. Further longitudinal studies are recommended.
Author Contributions

Conceptualization: Mary Naguib, Wael Abdel-Razek, Suzanne Estaphan, Eman Abdelsameea, Mohamed Abdel-Samiee, Nevine F. Shafik.

Data curation: Mary Naguib, Wael Abdel-Razek, Suzanne Estaphan, Eman Abdelsameea, Mohamed Abdel-Samiee, Nevine F. Shafik.

Formal analysis: Mary Naguib, Wael Abdel-Razek, Nevine F. Shafik.

Investigation: Mary Naguib, Nevine F. Shafik.

Methodology: Mary Naguib, Nevine F. Shafik.

Project administration: Mary Naguib, Nevine F. Shafik.

Supervision: Suzanne Estaphan, Eman Abdelsameea, Mohamed Abdel-Samiee.

Validation: Wael Abdel-Razek.

Visualization: Mary Naguib, Suzanne Estaphan, Eman Abdelsameea, Nevine F. Shafik.

Writing – original draft: Mary Naguib, Wael Abdel-Razek, Suzanne Estaphan, Nevine F. Shafik.

Writing – review & editing: Mary Naguib, Wael Abdel-Razek, Suzanne Estaphan, Eman Abdelsameea, Mohamed Abdel-Samiee, Nevine F. Shafik.

References

1. Organization WH. Global hepatitis report 2017. World Health Organization, 2017.
2. Gao Y, Yang J, Sun F, Zhan S, Fang Z, Liu X, et al. Prevalence of anti-HCV antibody among the general population in Mainland China between 1991 and 2015: a systematic review and meta-analysis. In: Open Forum Infectious Diseases. Oxford University Press US, 2019, p. ofz040.
3. Ministry of Health E, El-Zanaty, Associates E, and International I. Egypt Health Issues Survey. Ministry of Health and ICF International Cairo, Egypt and Rockville, MD, USA, 2015.
4. Waked I, Esmat G, Elsharkawy A, El-Serafy M, Abdel-Razek W, Ghalab R, et al. Screening and Treatment Program to Eliminate Hepatitis C in Egypt. New England Journal of Medicine 382: 1166–1174, 2020. https://doi.org/10.1056/NEJMrst1912628 PMID: 32187475
5. Essa M, Sabry A, Abdelsameea E, Tharwa E-S, and Salama M. Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. European Journal of Gastroenterology & Hepatology 31: 53–58, 2019. https://doi.org/10.1097/MEG.0000000000001250 PMID: 30247174
6. Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus–infected persons: results from ERCHIVES. Hepatology (Baltimore, Md) 62: 365–374, 2015. https://doi.org/10.1002/hep.27835 PMID: 25847403
7. MIHĂILĂ R-G, BOICEAN A, and BÎRLUŢIU V. The Connection between Hypercoagulability and Fibrogenesis in Chronic Liver Diseases. 2018.
8. Chaudhry R, Usama SM, and Babiker HM. Physiology, coagulation pathways. 2018.
9. Dhar A, Sadiq F, Anstee QM, Levene AP, Goldin RD, and Thuraz MR. Thrombin and factor Xa link the coagulation system with liver fibrosis. BMC gastroenterology 18: 1–9, 2018.
10. Chang JZC, Hsieh YP, Lin WH, Chen HM, and Kuo MYP. Activation of transforming growth factor-β1 by thrombin via integrins αvβ1, αvβ3, and αvβ5 in buccal fibroblasts: Suppression by epigallocatechin-3-gallate. Head & Neck 39: 1436–1445, 2017.
11. Tsuchida T, and Friedman SL. Mechanisms of hepatic stellate cell activation. Nature Reviews Gastroenterology & Hepatology 14: 397, 2017. https://doi.org/10.1038/nrgastro.2017.38 PMID: 28487545
12. Mancuso A. The ischemic liver cirrhosis theory and its clinical implications. Medical hypotheses 94: 4–6, 2016. https://doi.org/10.1016/j.mehy.2016.06.008 PMID: 27515188
13. Reitsma PH, Versteeg HH, and Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arteriosclerosis, thrombosis, and vascular biology 32: 563–568, 2012. https://doi.org/10.1161/ATVBAHA.111.242818 PMID: 22345594
14. Amara A, Mrad M, Sayeh A, Haggui A, Lahideb D, Fekih-Mrisa N, et al. Association of FV G1691A Polymorphism but not A4070G with coronary artery disease. *Clinical and Applied Thrombosis/Hemostasis* **24**: 330–337, 2018.

15. Campello E, Spiezia L, and Simioni P. Diagnosis and management of factor V Leiden. *Expert review of hematology* **9**: 1139–1149, 2016. https://doi.org/10.1080/17474086.2016.1249364 PMID: 27797270

16. Campello E, Spiezia L, Adamo A, and Simioni P. Thrombophilia, risk factors and prevention. *Expert review of hematology* **12**: 147–158, 2019. https://doi.org/10.1080/17474086.2019.1583555 PMID: 30773075

17. Tzoran I, Papadakis M, Brenner B, Fidalgo A, Rivas A, Wells PS, et al. Outcome of patients with venous thromboembolism and factor V Leiden or prothrombin 20210 carrier mutations during the course of anticoagulation. *The American journal of medicine* **130**: 482.e481–482.e489, 2017.

18. González-Reimers E, Quintero-Platt G, Martín-González C, Pérez-Hernández O, Romero-Acevedo L, and Santolari-Fernández F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. *World journal of gastroenterology* **22**: 4427, 2016. https://doi.org/10.3748/wjg.v22.i18.4427 PMID: 27182154

19. Pant A, Kopec AK, and Luyendyk JP. Role of the blood coagulation cascade in hepatic fibrosis. *American Journal of Physiology-Gastrointestinal and Liver Physiology* **315**: G171–G176, 2018. https://doi.org/10.1152/ajpgi.00402.2017 PMID: 29723040

20. Garcia-Tsao G, Abraldes JG, Berzigotti A, and Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology (Baltimore, Md)* **65**: 310–335, 2017.

21. Pugh R, Murray-Lyon I, Dawson J, Pietroni M, and Williams R. Transection of the oesophagus for bleeding oesophageal varices. *British journal of surgery* **60**: 646–649, 1973. https://doi.org/10.1002/bjs.1800600817 PMID: 4541913

22. Valett-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. *Hepatology (Baltimore, Md)* **46**: 32–36, 2007. https://doi.org/10.1002/hep.21669 PMID: 17567829

23. Wai C-T, Greeno JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology (Baltimore, Md)* **38**: 518–526, 2003. https://doi.org/10.1053/hep.2003.50346 PMID: 12883497

24. Elgharably A, Gomaa AI, Crosse MM, Norsworthy PJ, Waked I, and Taylor-Robinson SD. Hepatitis C in Egypt—past, present, and future. *International journal of general medicine* **10**: 1, 2017. https://doi.org/10.2147/IJGM.S119301 PMID: 28053553

25. Tsoschatzis EA, Crossan C, Longworth L, Gurusamy K, Rodríguez-Peralvez M, Mantzoukis K, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. *Hepatology (Baltimore, Md)* **60**: 832–843, 2014. https://doi.org/10.1002/hep.27296 PMID: 25043847

26. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, and Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. *Annals of internal medicine* **166**: 637–648, 2017. https://doi.org/10.7326/M16-2575 PMID: 28319996

27. Majumdar A, Kilsdon M, and Roberts S. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. *Alimentary pharmacology & therapeutics* **43**: 1276–1292, 2016. https://doi.org/10.1111/apt.13633 PMID: 27087015

28. Dak I, de Brijjine J, Takkenberg RB, Roelofs JJ, Tempelmans MJ, Dijkgraaf MG, et al. Factor XIII Val34-Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C. *Hepatology Research* **42**: 668–676, 2012. https://doi.org/10.1111/j.1872-034X.2011.00963.x PMID: 22385348

29. Menoreno MM, Aguilar SG, González EA, García SH, and González ER. Cryptogenetic liver cirrhosis and prothrombotic mutations—A mere association? *Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva* **108**: 588–591, 2016.

30. Yaman MH, Elwageh MM, Abd-Elnaby AY, and Eid MA. Factor V Leiden mutation in Egyptian patients with deep vein thrombosis. *Tanta Medical Journal* **44**: 53, 2016.

31. EL Baz RA, Ramadan MM, Fayad E, Shalhot AA, and Shershawy EME. Comparative Study on the Effect of Factor V Leiden and Prothrombin Gene Polymorphism in Preeclamptic Cases. *The Egyptian Journal of Hospital Medicine* **56**: 345–354, 2014.

32. Fawzy MS, Torain EA, Aly NM, Fakhr-Edeen A, Badran DI, and Hussein MH. Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study. *BMC cardiovascular disorders* **17**: 26, 2017. https://doi.org/10.1186/s12872-016-0456-3 PMID: 28086795
33. Essa HH, Gobran H, Sabry SM, and El-Dahshan DH. Thrombophilic gene polymorphisms are associated with deep venous thrombosis in a cohort of Egyptian patients. *The Egyptian Journal of Haematology* 44: 21, 2019.

34. Jadaon MM. Epidemiology of prothrombin G20210A mutation in the Mediterranean region. *Mediterranean journal of hematology and infectious diseases* 3: 2011. [https://doi.org/10.4084/MJHID.2011.054 PMID: 22220251](https://doi.org/10.4084/MJHID.2011.054 PMID: 22220251).

35. Plompen EP, Murad SD, Hansen BE, Loth DW, Schouten JN, Taimr P, et al. Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population: The Rotterdam Study. *Journal of hepatology* 63: 1459–1465, 2015. [https://doi.org/10.1016/j.jhep.2015.07.026 PMID: 26226452](https://doi.org/10.1016/j.jhep.2015.07.026 PMID: 26226452).

36. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. *Gut* 52: 1206–1210, 2003. [https://doi.org/10.1136/gut.52.8.1206 PMID: 12865283](https://doi.org/10.1136/gut.52.8.1206 PMID: 12865283).

37. Poujol-Robert Armelle, Rosmorduc Olivier, Serfaty Lawrence, Coulet Florence, Poupon Raoul, and Robert Annie. Genetic and acquired thrombotic factors in chronic hepatitis C. *Official journal of the American College of Gastroenterology: ACG* 99, no. 3: 527–531, 2004. [https://doi.org/10.1111/j.1572-0241.2004.04092.x PMID: 15056097](https://doi.org/10.1111/j.1572-0241.2004.04092.x PMID: 15056097).

38. Maharshak N, Halfon P, Deutsch V, Peretz H, Berliner S, Fishman S, et al. Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation. *World journal of gastroenterology: WJG* 17: 5007, 2011. [https://doi.org/10.3748/wjg.v17.i45.5007 PMID: 22174551](https://doi.org/10.3748/wjg.v17.i45.5007 PMID: 22174551).

39. Goulding C, O’Brien C, Egan H, Hegarty J, McDonald G, O’Farrelly C, et al. The impact of inherited prothrombotic risk factors on individuals chronically infected with hepatitis C virus from a single source. *Journal of viral hepatitis* 14: 255–259, 2007. [https://doi.org/10.1111/j.1365-2893.2006.00790.x PMID: 17381717](https://doi.org/10.1111/j.1365-2893.2006.00790.x PMID: 17381717).